Exploratory Clause Samples
An Exploratory clause defines the scope and terms under which parties may engage in preliminary discussions or investigations before entering into a formal agreement. Typically, this clause clarifies that any information exchanged or activities undertaken during the exploratory phase do not create binding obligations, except for specific provisions like confidentiality or exclusivity if stated. Its core function is to allow parties to assess the feasibility of a potential transaction or collaboration without committing to a final deal, thereby reducing risk and ensuring both sides can freely evaluate the opportunity.
Exploratory. Exploratory endpoints include: ▪ Change in MCC from Visit 1 (randomization) to Visit 3 (week 6) ▪ Proportions of subjects remaining on and off hypertonic saline and dornase alfa for up to 24 weeks after completion of each study ▪ Proportions of subjects with acute antibiotic use up to 24 weeks after completion of each study ▪ Average impact score at Visit 3 (Week 6) on subject perception of how stopping hypertonic saline or dornase alfa (or both) would impact their daily life 6 SUBJECT SELECTION
Exploratory leaves of absence to explore another pursuit may be granted teachers with at least three (3) years of service in the District. Leave applications for the following school year shall be in the hands of the Superintendent at least ninety (90) days prior to the end of the school year. In extra-ordinary circumstances this requirement will be waived. Leaves shall be granted upon written application and approval by the Board. Leaves shall be for one (1) year only.
Exploratory. Drilling
a) The Agency shall provide [Mention quantity of rigs] of Core drilling rigs with necessary accessories and manpower and other ancillary equipment for exploratory core drilling with NQ or equivalent size. In case of clays, agency shall undertake dry drilling.
b) The boreholes shall be vertical. Maximum deviation & drift of 1° is permissible.
c) For delineating the mineral/rock reserve vertically as well as horizontally and also to determine the total lithology, the Agency shall drill 10-15 nos. of wide spaced boreholes up to a depth of 200-250 meters at locations as instructed by CGM. The drilling may be stopped earlier at the instruction of CGM’s geologist or in case deccan trap is encountered earlier in that borehole.
d) Drilling of boreholes, if required, after studying the drilled borehole litho-logs and basin configuration, may be closed as per the instructions of CGM/GMRDS site Geologist.
e) While drilling wherever water table is encountered, depth of the water table shall be recorded and to be mentioned in the driller logs. Further, this data shall be mentioned in the final exploration report.
f) The core recovery in all the formation shall be at least 85% except in fault zone, weathered zone, soil, sand and structurally disturbed area.
g) In case of lower core recovery in normal geological conditions or jamming of the boreholes before completion of planned depth, re-drilling shall be carried out by the Agency at his own cost on the instruction of CGM/GMRDS representative. However the borehole location shall be at the nearest possible distance from the original borehole and Agency shall be free to do non-coring drilling up to the depth from where the core drilling is required with stipulated recovery.
h) Minimum Core Size required: 46 mm
i) Core should be preserved for future references in covered G.I. core boxes with a minimum of 22 Gauge GI sheet having lid with locking arrangements. Cores in core boxes shall be arranged by the agency with proper numbering and display pattern. Arrangement of core boxes shall be the responsibility of agency.
j) Preservation of cores shall be the responsibility of the Agency and it has to ensure that in no way the cores shall be misplaced or manipulated. The Drilling Agency shall make arrangements for transportation of the core boxes to the Petrography and Mineral Chemistry laboratory, Raisan, Gandhinagar or any other location as instructed by the field Geologist of CGM/ GMRDS. If the core is misplaced or l...
Exploratory. Determine baseline and post-vaccination influenza antibody titers by microneutralization (MN), in a subset of samples, against vaccine antigens following concomitant administration with mRNA vaccine or alone i. Proportion of participants in each vaccination group with a seroprotective MN (in a subset of samples) titer (≥1:40) pre- and post-ccIIV4 immunization for each 2023-24 influenza vaccine antigen ii. Proportion of participants in each vaccination group achieving MN (in a subset of samples) seroconversion (a titer ≥1:40 following ccIIV4 if the baseline titer is <1:10 or a four-fold rise in titer if the baseline titer is >1:10) following ccIIV4 vaccination for each 2023-24 influenza vaccine antigen iii. HAI (in a subset of samples) MN for each 2023-24 influenza vaccine antigen pre- and post-ccIIV4 in each vaccination group i. GMFR in MN (in a subset of samples) titers for each 2023-24 influenza vaccine antigen in each vaccination group Determine baseline and post-vaccination SARS-CoV-2 antibody binding titers and ACE2 binding inhibition and viral neutralization, on a subset of specimens, against mRNA COVID-19 vaccine antigens following concomitant administration with ccIIV4 or alone i. GMT for SARS-CoV-2 binding antibody titer and viral neutralization titer (for a subset of samples) pre- and post- vaccination with mRNA COVID-19 vaccine Determine duration and rate of waning of influenza HAI and MN antibody titers i. HAI and MN GMT for each 2023-24 influenza vaccine and circulating influenza virus antigens at visit 1, visit against ccIIV4 vaccine antigens and circulating influenza viruses 2, visit 3, and visit 4 for each vaccination group ii. Geometric mean fold change in HAI and MN titers for each vaccination group from visit 1 to visit 2, visit 3, and visit 4 for each 2023-24 influenza vaccine and circulating influenza virus antigen Determine duration of and rate of waning of SARS-CoV-2 antibody titers and viral neutralization titers, on a subset of samples, against mRNA COVID-19 vaccine antigens and circulating SARS-CoV-2 variants i. SARS-CoV-2 binding antibody and viral neutralization GMT for each mRNA COVID-19 vaccine and circulating SARS-CoV-2 virus antigens at visit 1, visit 2, visit 3, and visit 4 for each vaccination group ii. Geometric mean fold change in SARS- CoV-2 and viral neutralization (in a subset of samples) titers for each vaccination group from visit 1 to visit 2, visit 3, and visit 4 for each COVID-19 Moderna mRNA COVID-19 vaccine a...
Exploratory. To compare the percentage of bardoxolone methyl and placebo patients who experience an increase from baseline in eGFR of 30% or more after 48 weeks of treatment. • To compare the percentage of bardoxolone methyl and placebo patients who experience a decrease from baseline in eGFR of 30% or more after 48 weeks of treatment. • To assess the distribution of changes from baseline in eGFR in bardoxolone methyl versus placebo patients after 48 weeks of treatment. • To compare the percentage of bardoxolone methyl and placebo patients who experience an increase from baseline in eGFR of 30% or more after 100 weeks of treatment. • To compare the percentage of bardoxolone methyl and placebo patients who experience a decrease from baseline in eGFR of 30% or more after 100 weeks of treatment. • To assess the distribution of changes from baseline in eGFR in bardoxolone methyl versus placebo patients after 100 weeks of treatment. • To assess the Patient Global Impression of Change (PGIC) scores in bardoxolone methyl- treated patients relative to placebo after 48 weeks of treatment. • To assess the Clinical Global Impression-Improvement (CGI-I) scores in bardoxolone methyl- treated patients relative to placebo after 48 weeks of treatment. • To assess the Patient Global Impression of Change (PGIC) scores in bardoxolone methyl- treated patients relative to placebo after 100 weeks of treatment. • To assess the Clinical Global Impression-Improvement (CGI-I) scores in bardoxolone methyl- treated patients relative to placebo after 100 weeks of treatment.
Exploratory. Throughout the semester, students will explore various aspects of technology, software, programming, and digital citizenship. By the end of the course, students will be equipped with the knowledge and skills necessary to navigate the digital age confidently.
Exploratory. To evaluate: • the CST Area under the Curve (AUC) • the percent of eyes with resolution of fluid (sub-retinal fluid and intraretinal cysts) on SD-OCT
Exploratory. Students with majors in the College of Arts and Sciences (CAS) must satisfy an exploratory requirement. This can be done by completing a double major or a CAS minor or concentration; or by completing a minimum of 12 credits in a single CAS rubric, outside of their major rubric. For additional options visit ▇▇▇▇▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇▇. Only courses that are at the 100-level or above may be used to fulfill the exploratory requirement. Students using MTA or MACRAO must complete the exploratory requirement at Oakland University or another four-year institution.
Exploratory. WELLS 10.1 Operations by All Parties 12 10.2 Second Opportunity to Participate 12 10.3
Exploratory. Learn about agriculture and its related fields through research, interviewing industry professionals, or attending open houses or field days. This type of project allows the student to explore any aspect of agriculture that interests them. A two-page typed report must be completed with sources cited. Examples: Observe a veterinarian or research report on food science careers.